Trial updates offer insights on sirolimus in CLTI patients

The peripheral arterial and chronic limbthreatening ischaemia (CLTI) session yesterday afternoon provided delegates with a consensus update and insight into potential advances in this area. The sirolimus drugcoated device section of the session provided updates on three belowthe-knee (BTK) studies, as well as insight into a real-world experience of sirolimus-coated balloon versus conventional balloon angioplasty for CLTI.

Attendees also responded in real time to the statement ‘sirolimus is the answer’—the poll results showed that a plurality of audience members who answered the poll agreed with the statement. These delegates in favour of the motion comprised 56% of respondents, whereas 44% of respondents believed sirolimus was not the answer.

Peter Gaines (Sheffield, United Kingdom) opened the session, offering attendees an update on the SELUTION4BTK trial of a sirolimus drug-coated balloon (DCB) in BTK arteries.

Following Gaines came Edward Choke (Bukit Merah, Singapore), who spoke about his centre’s experience comparing sirolimus DCB and conventional balloon angioplasty in patients with CLTI.

Ramon Varcoe (Sydney, Australia) took over from Gaines at the podium, to present the 12-month results from the SWING BTK multicentre study, evaluating a sirolimus DCB.

Rounding off this section of the afternoon’s programme was Marianne Brodmann (Graz, Austria), with an update on the RESOLV study, which is evaluating a bioabsorbable sirolimus-coated scaffold for BTK treatment.